Validation of dynamic risk stratification in pediatric differentiated thyroid cancer
- PMID: 28822062
- DOI: 10.1007/s12020-017-1381-7
Validation of dynamic risk stratification in pediatric differentiated thyroid cancer
Abstract
Purpose: There has been increasing interest in a risk-adopted management strategy known as dynamic risk stratification following the revised American Thyroid Association guidelines for differentiated thyroid cancer. We aimed to evaluate the usefulness of dynamic risk stratification for predicting structural disease in pediatric differentiated thyroid cancer patients.
Methods: We retrospectively reviewed 130 pediatric differentiated thyroid cancer patients (≤19 years) who were treated between 1996 and 2015 at Samsung Medical Center. Patients were stratified according to three American Thyroid Association initial risk group (low, intermediate, or high risk) and four dynamic risk stratification group (excellent, indeterminate, biochemical incomplete, or structural incomplete).
Results: Based on dynamic risk stratification strategy, structural disease was identified 3.9% in the excellent group, 9.7% in the indeterminate group, 76.9% in the biochemical incomplete group, and 100% in the structural incomplete group. The hazard ratios of the structural disease were 18.10 (P < 0.001) in the biochemical incomplete group, and 19.583 (P < 0.001) in the structural incomplete group compared to the excellent group. The prevalence of structural disease also increased as American Thyroid Association initial risk classification increased (5.9% in the low-risk group, 13.6% in the intermediate-risk group, and 45% in the high-risk group). The hazard ratios of structural disease in the high-risk group was 10.296 (P < 0.001) in compared to the low-risk group.
Conclusion: Dynamic risk stratification based on patient responses to initial therapy was able to effectively predict the risk of structural disease in a pediatric population, and as a follow-up strategy, may work as well in pediatric differentiated thyroid cancer patients as it does in adult differentiated thyroid cancer patients.
Keywords: Differentiated thyroid cancer; Dynamic risk stratification; Pediatric.
Similar articles
-
Initial and Dynamic Risk Stratification of Pediatric Patients With Differentiated Thyroid Cancer.J Clin Endocrinol Metab. 2017 Mar 1;102(3):793-800. doi: 10.1210/jc.2016-2666. J Clin Endocrinol Metab. 2017. PMID: 27809646
-
Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.Thyroid. 2017 Apr;27(4):524-530. doi: 10.1089/thy.2016.0477. Epub 2016 Dec 23. Thyroid. 2017. PMID: 27869547
-
Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.Nucl Med Commun. 2017 Mar;38(3):228-233. doi: 10.1097/MNM.0000000000000636. Nucl Med Commun. 2017. PMID: 27984538
-
Dynamic risk stratification in the follow-up of thyroid cancer: what is still to be discovered in 2017?Endocr Relat Cancer. 2017 Nov;24(11):R387-R402. doi: 10.1530/ERC-17-0270. Epub 2017 Aug 18. Endocr Relat Cancer. 2017. PMID: 28821573 Review.
-
Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature.Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019 May-Jun;38(3):195-203. doi: 10.1016/j.remn.2018.12.008. Epub 2019 Feb 8. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019. PMID: 30745131 Review. English, Spanish.
Cited by
-
Differentiated Thyroid Cancer in Children and Adolescents: Long Term Outcome and Risk Factors for Persistent Disease.Cancers (Basel). 2021 Jul 24;13(15):3732. doi: 10.3390/cancers13153732. Cancers (Basel). 2021. PMID: 34359632 Free PMC article.
-
The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old.J Clin Res Pediatr Endocrinol. 2022 Jun 7;14(2):196-206. doi: 10.4274/jcrpe.galenos.2022.2021-10-4. Epub 2022 Feb 9. J Clin Res Pediatr Endocrinol. 2022. PMID: 35135184 Free PMC article.
-
Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline.Endocr Relat Cancer. 2022 Sep 7;29(11):G1-G33. doi: 10.1530/ERC-22-0035. Print 2022 Nov 1. Endocr Relat Cancer. 2022. PMID: 35900783 Free PMC article.
-
Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy.J Clin Endocrinol Metab. 2023 Nov 17;108(12):3338-3344. doi: 10.1210/clinem/dgad322. J Clin Endocrinol Metab. 2023. PMID: 37265226 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical